• Could the Lifesaving Promises of Golden Rice FINALLY be Realized?

    On this page we usually tout the newest examples of biotechnology innovation: jet fuels made from algae; gene edited bananas that resist disease; soil microbes that reduce the need for chemical inputs like fertilizer; and bio-based products that are more environmentally friendly. The list of next generation innovation goes on and on with inspirational stories of biotech’s promise to improve our planet, our society and our economy.
    Sadly, after two decades, there remain technologies in the
  • CMS’s Own Data Do NOT Support Claims on Part B Drug Spending

    In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for Politico Pulse note:
    “The agency [Centers for Medicare & Medicaid Services] on Friday announced a $9 monthly premium increase and $13 annual deductible hike, but argued that the White House is working to bring down cost drivers for seniors.
    “The increase in the Part B premiums and deductible is largely due to rising spending on physician-administered drugs,” CMS said in its announ
  • In Speaker Pelosi’s Extreme Drug Pricing Bill, Funding for NIH is MIA

    Supporters of Speaker Pelosi’s extreme drug pricing bill (H.R. 3) want us to believe that they can destroy the biopharmaceutical industry and still produce new cures and treatments for patients in need. The crux of this fairy tale is the promise by supporters of H.R. 3 to reinvest “savings” from the bill back into the National Institutes of Health (NIH). But there are two significant problems with this empty promise.
    Problem #1: H.R. 3 does NOT reinvest savings back into the NI
  • Synthetic Biology to Sustain Agriculture and Transform the Food System

    For some, the term “synthetic biology” can bring back nightmares of the infamous college course that all students failed at least one. But what was once a roadblock to receiving a bachelors degree in science, is quickly turning into a robust field of biotechnology that is showing potential to transform how we manufacture products and grow food.
    Synthetic biology can be used to develop renewable chemicals to create products like synthetic rubber for tires or bioplastics
  • Advertisement

  • GMOs and Animal Feed – Getting the Facts

    People have a lot of questions about GMOs. One of the top questions people have is about GMOs in the grocery store. But most people don’t know that much of the GMO crop production around the world goes to helping feed animals.  In fact, genetically modified crops have benefited the livestock sector by helping to increase yields of the crop, having higher quality traits, and are safer for livestock to eat than feed in the past. The GMO crops that are used in animal feed and p
  • Expanding Benefits to Members, BIO Now Offering Education and Training Courses

    BIO is continually looking for ways to help its members grow and prosper. This week BIO announced a partnership with Biotech Primer Inc.—a training organization helping professionals understand the science, business, and regulatory processes essential to the biotech industry. Since its start in 2001, Biotech Primer has trained over 65,000 life science professionals worldwide.
    Biotech Primer and BIO are joining forces to offer online training/education to the BIO Membership community and bi
  • The Pelosi Plan and “Me Too” Drugs

    Supporters of Speaker Pelosi’s drug pricing plan (H.R. 3) claim the bill will discourage the development of so-called “me too” drugs. For example, Rep. Donna Shalala was recently quoted as saying: “I think it actually will reduce me-too drugs … I think [pharmaceutical companies] are going to clean their portfolios. … I think that they’ll become more efficient.” There’s just one problem: HR 3 is designed to have the opposite effect
  • #BIOSummit19 Concludes with Message of Hope Offered by Innovation

    Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event’s chief convener, added: “I am BIO, but we need BIO.”
    “We’re poised on the precipice of scientific possibility, there’s enormous potential for sci
  • Advertisement

  • Australia is rich but unsophisticated, says Harvard. But is it true?

    A recent Harvard study found Australia's economy is less complex than Kazakhstan or Uganda, but is the assessment fair? And, if it is, what can be done to diversify the economy away from its mining dependence?
  • FDA Discusses Effective Patient Engagement at #BIOSummit19

    For the FDA, engagement with patients, caregivers and patient advocacy organizations is a vital part of the drug development and review process. However, how that engagement happens can determine how successful it is.
    This was the key question addressed by the “Practices and Principles: Navigating the FDA” panel on day one of BIO’s Patient and Health Advocacy Summit. 
     
    “It’s really been heartening to see the ways that not just the FDA but industry is inco
  • #BIOSummit19: Education and Partnerships Raise Awareness

    When Mark Dant’s son Ryan was first diagnosed with MPS-I, a rare genetic disorder that leads to organ damage, he had to buy a medical dictionary in order to decipher the words the doctors were saying to him.
    “I didn’t understand the language of the scientists,” Dant recalled. “The key for every advocate is education. Once I was able to understand the basic terminology, I was able to ask the right questions. It’s not someone else’s responsibility to teach
  • Our Farms, Our Food and Our Future Depend on Climate Change Solutions

    “We really need to wake up quickly,” Al Gore told The Washington Post in an interview about the looming food crisis caused by climate change. …“But technology and science has an important role to play,” Gore stated.
    Farmers can be part of the climate change solution by cutting greenhouse gas emissions, increasing carbon sequestration and making farms more resilient, according to a Capitol Hill hearing this week.
    “Anyone who eats should care about the climate
  • Greenwood: Solving the Looming Superbug Crisis Will Require Bold Action From Congress

    Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones.
    “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates show that it takes more than a decade to develop a new antibiotic or vaccine and can cost more than $1 billion. But even when a product does make it to the market, it mi
  • Ready for Takeoff: Sustainable Fuels are Decarbonizing our Skies

    As the world’s largest business aviation trade show takes place in Las Vegas, a Congressional hearing on climate change and clean power convenes on Capitol Hill. Sustainable aviation fuels took center stage at both and was highlighted as one tool that is helping to decarbonize the U.S. transportation sector.
    The National Business Aviation Association’s (NBAA) week-long Convention & Exhibition event is showcasing sustainability. As part of the event’s aircraft display, all t
  • Fundraising Companies Find Strategic Partners that Best Fit Their Stage of Development at BIO Investor Forum

    Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors from around the world, with increased representation from the Asia markets, have sought out and met with the myriad of biotechs ready to spotlight their promising developments.
    Attendance set a n
  • IPOs Are a Gateway to More Diverse Biotech Boards

    As more biotechnology executives begin to focus on strategies to diversify their boards to avoid groupthink and strengthen corporate governance, an emerging consensus is forming that initial public offerings are a key gateway to assembling higher-performing leadership teams.
    That was the unanimous consensus of a panel of experts who explored the topic at the BIO Investor Forum on Tuesday in San Francisco. The topic is especially timely for biotech companies headquartered in California, which las
  • Investment Crackdown Prompts Chinese Investors to Leave U.S. Biotech Market and Focus on Europe

    Confusion among Chinese investors about shifting U.S. regulatory policy is draining billions of dollars from the American biotechnology sector and stressing startups that rely on foreign capital to cure disease.
    That was the message of James Huang, a managing partner in Kleiner Perkins’s China office who specializes in facilitating cross-border deal financing. He told attendees at the BIO Investment Forum that the Trump administration’s new rules scrutinizing foreign investment
  • Gene Therapies: The Pipeline Towards a New Era for Patients

    On Tuesday morning at the BIO Investor Forum, leaders from top companies at the forefront of gene therapy innovation assembled to discuss successful approaches, challenges in protein delivery, and the future of expanding this class of medicines.
    Gene therapies have the potential to increase the healthspan of patients and offer new approaches to treating diseases, with a sizable pipeline in development. Early leaders in the field have focused on rare diseases which continues to open the path
  • New BIO One-on-One Partnering Mobile App

    BIO has released a new and improved mobile app for the BIO One-on-One Partnering™ system. After intensive surveys and interviews with attendees who have engaged in partnering at BIO business development & investor events around the world, we revamped our partnering mobile app to make the process of managing your partnering experience even easier.
    The new app, available for free in the App Store and Google Play Store, has a streamlined interface that is designed to put key information a
  • BIO’s Week with Food and Ag Leaders

    Meatless Burgers. Gene edited crops. Changing diets.
    Nothing was off the table this week as BIO engaged in two pivotal discussions focused on the future of agriculture and food.
    On Monday, Dana O’Brien, vice president for BIO’s food and agriculture section, attended the Wall Street Journal’s Global Food Forum in New York City.
    At the event, leaders from USDA and several food companies, including McDonald’s, Cargill and Mondelez, were on hand to discuss the next breakthrou
  • BIO Mourns Passing of Dr. John Holaday

    On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away.
    Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed Army Institute of Research as an Army captain, and later as head of the Neuropharmacology Department. Holaday was also a professor at both Johns Hopkins University and the Uniformed Services Univ
  • BIO’s Leadership Transition | “The fight continues…”

    On Tuesday, October 8, BIO formally announced that its President and CEO Jim Greenwood would be stepping down from the world’s largest biotechnology organization in January 2021. In a letter to BIO staff, Greenwood reflected on his rise to BIO and the accomplishments the organization has achieved through his vision. But, as Jim notes, “The fight continues…”
    Read the full letter below.
    When I was a college student during the tumultuous years of 1969 to 1973, I dedica
  • Bringing Modern Agriculture to the People

    Earlier this year, the Farm Journal Foundation (FJF) announced that it has entered into a two-year cooperative agreement with USDA’s Agricultural Marketing Service (AMS) to share the story of how food travels from seed to table through a new Modern Ag Garden on the National Mall.  We talked to Jay Vroom, chair of the Farm Journal’s Trust in Food initiative and strategic advisor to the Farm Journal Foundation, about this exciting new initiative about how it can help people connec
  • Climate Week: Biofuels to Decarbonize Air Travel

    Last week Greta Thunberg took the United States by storm. She continued her mission of raising the alarm on climate change by visiting the United States for Climate Week and the United Nation’s Climate Summit during its General Assembly in New York City.
    The Swedish teenager arrived in the Big Apple after a two-week boat trip from Europe across the Atlantic Ocean. The young climate activist refused to travel by plane because of aviation’s significant carbon footprint.
  • Doing Agritourism Right

    Recently, I had the distinct pleasure of representing GMO Answers at the National Association for State Departments of Agriculture (NASDA) annual meeting in Albuquerque, New Mexico.  It was a great opportunity to learn about the different ag issues states across the country are facing. For example, big dairy states like Wisconsin, Vermont, and New York are having trouble with small dairies closing because they are not economically sustainable in this economy. States in the Midwest are facin
  • Making Alzheimer’s Treatments a Priority

    Alzheimer’s is one of the most feared diseases in the world. Despite many attempts to find an effective therapy to prevent or delay its effects, the disease remains largely untreatable. Many of us know someone with Alzheimer’s. For me, it was my father who was faced with early onset of the disease. By his mid-sixties he started showing signs of Alzheimer’s that were often dismissed as forgetfulness and aging. Living in a rural area, even after seeking medical cou
  • Buzz of BIO Winners for the 2019 BIO Investor Forum

    After receiving a record number of nominations, we are pleased to announce our winners for the 2019 Buzz of BIO contest of the BIO Investor Forum!
     WINNER: Early Stage Entrepreneur
     
    SciBac creates live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. The company improves beneficial microorganisms by using its MERGE (Microbial Enhanced Recombinants Generated by Evolution) platform that can quickly, naturally and safely transfer useful geneti
  • Imagine A World Without Chocolate | #FutureOfFood Summit Highlights Gene Editing’s Potential

    For the first time, the Future of Food Summit was co-hosted by the International Food Information Council Foundation (IFIC) and EatingWell—a magazine focused on food culture.
    And while IFIC has long hosted the annual event, the addition of EatingWell provided a new perspective on the intersection of technology and diet trends.
    As part of that discussion, the summit highlighted the role that gene editing can play in protecting the future of foods.
    Mark Guiltinan, professor of plant molecula
  • BIO International Convention Aims to Go BEYOND

    The 2020 BIO International Convention is heading back to San Diego, California next June, and planning is well underway! First order of business? Announcing our theme. This year we reflect on the passion, drive and risk-taking of an industry that consistently strives to accomplish things that others might deem impossible—an industry that goes BEYOND.
    This theme represents the collective efforts and perseverance to develop solutions that go beyond our wildest dreams. We don’t just ove
  • #TBT: Debunking Some Common Myths on Patent Protections

    The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is set to examine the U.S. patent system this morning. Ahead of the hearing – and in honor of #ThrowBackThursay – we are resurfacing a piece by BIO’s Tom DiLenge that helps debunk some of the most common myths surrounding intellectual property and the biopharmaceutical industry.
    **
    I-MAK’s Distorted View of the U.S. Patent System
    July 5, 2018
    In an opinion piece published at&
  • BIO Hosts 2019 BIO Latin America Conference in Brazil

    The 5th BIO Latin America was held September 3-4 in the largest metropolis in the Western Hemisphere – Sao Paulo, Brazil. The BIO Latin America Conference, co-hosted by BIO and Biominas Brazil, has solidified itself as the premier life sciences meeting in the Latin America, welcoming over 675 attendees from 28 countries from around the world, approximately 10% growth over the previous edition. In addition, there were over 350 companies represented and more than 800 meetings conducted throu
  • Will the RFS Deal Protect Innovation and Our Planet?

    “As we speculate on the details and implications of the administration’s renewable fuels deal, the future of an entire green industry hangs in the balance,” writes Stephanie Batchelor, VP of BIO’s Industrial and Environmental Section in Biofuels Digest.
    The biofuels industry is still feeling the sting from President Trump’s decision to grant refinery waivers to oil companies under the Renewable Fuel Standard. Since then, the Administration has been trying
  • Tackling Hepatitis C Hand in Hand with Communities

    “For years of my life, I’ve let myself be defined by the words of others. Addict, junkie, criminal. With all those labels, it’s so much harder to go get tested for hepatitis C and add one more notch to that.” Those are the powerful words of Cat, a harm reduction advocate from North Carolina—one of five states I visited earlier this year in greater Appalachia—where the opioid epidemic is taking an enormous toll on individuals, families and communities. Sadly, t
  • The Challenges and Risks of Adopting Foreign Price Controls

    The Trump Administration is moving forward with a plan to import foreign price controls into Medicare. Under the proposed International Pricing Index (IPI) model, the federal government would move away from a long-standing market-based reimbursement system to one that is tied to prices paid in countries with single-payer health care systems.
    Here’s how the current system works. Under Medicare Part B, the government reimburses payers for medicines that are administered directly by providers
  • As Mosquito Fears Rise, EPA Considers Oxitec 2nd Generation Trial

    Most people consider mosquitoes to be a summertime pest – the unwelcome guest at the backyard barbecue. More concerning are the threats from disease-carrying mosquitoes, those that can potentially result in Dengue, West Nile, Yellow fever and Zika. And now media are reporting alarming cases of Eastern equine encephalitis (EEE) in the United States that have already killed at least three people and infected others.
    That’s why yesterday’s Environmental Protection Agency (EPA) Fed
  • This Fashion Month, Learn About the Benefits of GMO Cotton

    Even as this year’s New York Fashion Week comes to a close, it’s important to remember that all of September is considered Fashion Month. After all, it IS called The September Issue!
    And given that it is Fashion Month, it’s a good time to learn about the benefits of one of the lesser talked about GMOs: cotton. Cotton provides more than just apparel and home furnishings, however. Every part of the cotton plant can be used. The long cotton fibers are used to make cloth, the
  • ICYMI: Biopharmaceutical Companies Aren’t Free-Riding on Government Research

    Writing for the Boston Globe, Dr. Michael Rosenblatt, chief medical officer of the venture firm Flagship Pioneering, debunks the common myth that biopharmaceutical companies are “free-riding” on government research.
    Policymakers in Washington have long preferred to believe that scientists and researchers funded by federal taxpayer dollars discover medicines on their own, and that innovative biotech’s simply take advantage of this work and profit as result. But “nothing co
  • From Treatments to Cures – BIO Partnering Sets the Stage

    The fight against HIV has moved off the front pages. Advancements in antiretroviral drugs are allowing people living with HIV to live normal lives. By reducing the “viral load”, these treatments give the immune system a chance to recover and allow the body to fight off infections and certain cancers.
    That’s the good news.
    Yet managing a disease is not the same as curing it. HIV patients must endure the onerous daily routine of ingesting a combination of therapies that typically
  • More Meetings, More Results with BIO One-on-One Partnering

    Innovate Biopharmaceuticals has had more meetings through BIO’s One-on-One Partnering™ than they can count. In fact, it is the principal way the company meets candidates for both in-licensing and out-licensing arrangements. Participating for at least six years, the company points out that in the last three years, alone, it has had over 300 meetings scheduled through the system.This is the second in a series recognizing one of BIO’s
    Triple Crown PartnersKendyle Woodard, Co-found
  • Nominate Your Company to be the Buzz of BIO!

    Is your company seeking a next round of financing or hoping to make the valuable connection needed to take your product into the next phase? Nominate your company and enter the Buzz of BIO contest at the BIO Investor Forum.
    Ten biotechs will be selected in each of the three categories, “Early Stage Entrepreneurs”, “Late Stage Leaders” and “Diagnostics and Beyond”. Please note that this contest is restricted to companies headquartered in the U.S.
    Buzz
  • Pitch Perfect – Storytelling is Key for BIO One-on-One Partnering

    Keith Ignotz knows the power of a good story. The President & CEO of OcuMedic—an early stage biotech company developing a novel pre-and post-eye surgery treatment to replace eye drops—has made significant inroads telling the OcuMedic story since he assumed his role in early 2018. Some of his success can be attributed to his reliable presentations at BIO’s events including One-on-One Partnering. Indeed, Ignotz’s delivery garnered him a Start-up Stadium win at the
  • Wine Without the Whine

    Biotechnology brings better grapes AND hangover relief!
    As you consider your holiday menu and shopping list for the Labor Day weekend, drink a toast to science and innovation for enhancing many of our staple foods – and beverages!It’s no secret that biotechnology helps repel insect pests so – whether white or yellow, that ear of corn is tasty and wormless. Biotechnology also makes non-browning apples for your fruit salad, and brings healthy, sustainably grown Atlantic salmon to
  • Discrimination Against Vulnerable Patients Is Nothing New

    Transformative therapies are advancing like never before, and a new class of medicines are changing the way we treat the world’s most devastating and debilitating diseases. Yet while innovative biopharmaceutical companies are doing their part in developing lifesaving products for patients, discriminatory insurance barriers are often standing in the way.
    Insurance Discrimination Is A Growing Problem
    Since May, when a breakthrough gene therapy to treat spinal muscular atrophy (SMA) was appro
  • National Immunization Awareness Month Is a Reminder About the Value of Vaccines

    Writing for Morning Consult, Dr. Judy Monroe, president and CEO of the CDC Foundation, highlights the importance of immunization as August marks National Immunization Awareness Month.
    “As an international public health community, we have eradicated the scourge of smallpox thanks to Edward Jenner’s research and the development of the world’s first vaccine. We are nearing the eradication of polio thanks to the commitment and research of Jonas Salk and Albert Sabin. Most recently,
  • The Strong Keep Getting Stronger: Why the Bay Area Remains #1 Biotech Hub for VC Investing

    Whether you come to the Bay Area for the entrepreneurial talent, venture capital investment or biotech innovation, this trifecta conjures the perfect storm for regional economic success.
    The enduring strength of the Northern California life science cluster attracts small biotech startups, which are subsequently finding massive success as venture capitalists turn their gaze from social networking and tech – industries that are inextricably associated with San Francisco and the greater Bay A
  • The BIO Investor Forum Links Promising Early-Stage Technologies with an Active Investor Network

    As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in 2018.  In 2018, venture capital funding of private emerging therapeutic companies also reached a decade high of $12.3 billion, a 56% ($4.4 billion) increase from the prior record set in
  • Prince Harry, Meghan Markle, and… Biofuels?

    The Duke and Duchess of Sussex—Prince Harry and Meghan Markle—have made some headlines this week… albeit one they probably don’t prefer. Why? Well, the royal couple took four private flights in 11 days while campaigning against climate change and some have been critical of that fact.
    This write-up, however, is not critical of Prince Harry and Meghan Markle. I don’t expect the British royal family to fly commercial airlines for obvious reasons and concerns. Let&rsqu
  • New Coalition to Raise Awareness of Antimicrobial Resistance Threat, Call for Urgent Solutions

    The Biotechnology Innovation Organization (BIO), leading scientists, public policy experts, and industry leaders today announced the launch of “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance and advocate for policies that accelerate the creation of new medicines.
    Each year, it is estimated antimicrobial resistance (AMR) claims nearly 25,000 lives nationwide and nearly 700,000 across the globe, according to
  • BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

    BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford.
    Watch the full segment below.
  • Some GMO Basics

    Discussions about genetically modified organisms (or GMOs) are all over the mainstream media and on Facebook, Twitter, and Instagram. Lots of people have strong opinions about them. Some support the technology, while others adamantly oppose them.
    But how much do people know about them?  Yes, certainly we have been modifying our food for thousands of years, and many of the crops we eat today, through various breeding methods, look much different than they did 50, 100, and 500 years ago. But

Follow @Biotech_News_AU on Twitter!